Shanghai Haohai Biological Technology Co (SHSE:688366) EBIT: ¥115 Mil (TTM As of Mar. 2026)


SHSE:688366 Shanghai Haohai Biological Technology Co Ltd SHSE:688366
69 GF Score
Price ¥28.61
GF Value ¥43.53
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co EBIT?

Shanghai Haohai Biological Technology Co SHSE:688366 -3.57% 69 EBIT is ¥115 Mil as of Mar. 2026. GuruFocus rates SHSE:688366 with a GF Score™ of 69/100 and a GF Value™ of ¥43.53 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Shanghai Haohai Biological Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥99 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥115 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai Haohai Biological Technology Co's annualized ROC % for the quarter that ended in Mar. 2026 was 5.81%. Shanghai Haohai Biological Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai Haohai Biological Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.77%.

Shanghai Haohai Biological Technology Co  (SHSE:688366) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai Haohai Biological Technology Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=302.648 * ( 1 - 25.56% )/( (3903.298 + 3850.465)/ 2 )
=225.2911712/3876.8815
=5.81 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6720.063 - 294.682 - ( 2522.083 - max(0, 914.671 - 3462.813+2522.083))
=3903.298

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6666.309 - 403.613 - ( 2412.231 - max(0, 908.501 - 3389.949+2412.231))
=3850.465

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai Haohai Biological Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=394.22/( ( (1816.488 + max(296.723, 0)) + (1667.709 + max(286.884, 0)) )/ 2 )
=394.22/( ( 2113.211 + 1954.593 )/ 2 )
=394.22/2033.902
=19.38 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(271.004 + 522.875 + 82.923) - (294.682 + 0 + 285.397)
=296.723

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(250.974 + 538.972 + 124.145) - (403.613 + 0 + 223.594)
=286.884

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai Haohai Biological Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=115.349/4165.828
=2.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co EBIT Related Terms

Shanghai Haohai Biological Technology Co EBIT Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co EBIT Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 387.61 243.33 515.56 484.21 258.12

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.79 0.00 112.55 -95.75 98.56

SHSE:688366 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Haohai Biological Technology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's EV-to-EBIT falls into.


SHSE:688366
69GF Score
Shanghai Haohai Biological Technology Co Ltd SHSE:688366
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥115 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥115 Mil mean?
Shanghai Haohai Biological Technology Co (SHSE:688366) has a EBIT of ¥115 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Haohai Biological Technology Co.
Is Shanghai Haohai Biological Technology Co's EBIT too high?
Shanghai Haohai Biological Technology Co's current EBIT is ¥115 Mil. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's EBIT compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's EBIT of ¥115 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Haohai Biological Technology Co. Shanghai Haohai Biological Technology Co's current EBIT is ¥115 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (SHSE:688366) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥43.53, compared to a current price of ¥28.61 — trading 34.3% below its estimated fair value. The current EBIT is ¥115 Mil. Shanghai Haohai Biological Technology Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (SHSE:688366), the current EBIT is ¥115 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (SHSE:688366) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of ¥28.61 is trading 34.3% below its estimated GF Value™ of ¥43.53. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for SHSE:688366:

  • EBIT: ¥115 Mil
  • GF Value™: ¥43.53 vs. price of ¥28.61 (34.3% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688366 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong5HB:Germany
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
69GF Score

Get the complete analysis for SHSE:688366

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.61
Price
¥43.53
GF Value